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To determine the concentration of various blood biomarkers associated with digestion in
healthy horses treated with different doses of omeprazole (OMPZ), four Arabian horses
without gastric ulcers were selected and distributed in one factorial with four oral treat-
ments (Control; OMPZBOLUS; OMPZ4mg/kg; OMPZ1mg/kg). Control did not receive any treat-
ment. OMPZBOLUS were given 4 mg/kg of omeprazole in a single dose on the day before blood
sampling. In the OMPZ4mg/kg and OMPZ1mg/kg treatments, horses were treated over 11 days.
All treatments were performed 16 hours before morning feeding. The “washout” period was
21 days between rounds. After an overnight fasting period, blood samples were collected
from all animals (T1), after which the animals received supplementation, and blood samples
were collected after 30 minutes (T2), 1.0 hours (T3), 1.5 hours (T4), 2.0 hours (T5), 3.0 hours
(T6), 4.0 hours (T7), 5.0 hours (T8), 6.0 hours (T9), and 7.0 hours (T10). Blood samples were
analyzed for total plasma protein (TPP), glucose, urea, creatinine, uric acid, cholesterol, tri-
glycerides, calcium, phosphorus, and magnesium. The results showed differences between
treatments for urea, cholesterol, uric acid; between phases for glucose; and between phase
and treatment for creatinine, triglycerides, phosphorus, and magnesium; however, there was
no difference for TPP and calcium between treatment and between phases. Oral adminis-
tration of OMPZ in healthy equines interfered with the metabolism of digestion biomarkers
of lipid, mineral, and protein metabolism, although the animals were treated for a maximum
of 11 days. Horses treated with a proton-pump inhibitor need to be evaluated regularly to
avoid signiﬁcant modiﬁcation in their metabolic parameters.
 2014 Elsevier Inc. All rights reserved.1. Introduction
Gastric ulcer syndrome in equines is an important factor
that compromises the performance of equine athletes.
It occurs with high frequency in these animals, varying
between 60% and 90% [1,2]. This elevated morbidityanso Filho, Equine
ambuco, Recife, Per-
o Filho).
. All rights reserved.has motivated the adoption of preventative treatments to
reduce the occurrence of gastric ulcers among equine
athletes. Several medication regimens can be used as pre-
ventative treatments.
Management strategies are based mainly on decreasing
gastric acidity, maintaining the pH above 4, covering the
ulcers with an agent that is resistant to acid, and stimu-
lating the release of protective factors in the gastric mucosa
[2]. Proton-pump inhibitors (PPIs) have been primarily
used for ulcer treatment, relieving the symptoms and
creating a favorable environment for wound healing [3,4].
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treatment is not without side effects, most likely because
the reduction of gastric pH can modify digestion and the
absorption of nutrients throughout the digestive tract,
changing the concentration of some biomarkers in the
blood [5–9].
Omeprazole (OMPZ), which has been widely used in
athletic horses, acts by lowering gastric pH by reducing
production of the acid pentagastrin [10]. It is the only agent
that is allowed for use in horses, which inhibits the proton
pump, and several studies demonstrate the safety and ef-
ﬁcacy of oral administration in foals and adult horses,
healing more than 75% of the horses treated and kept in
training [11,12]. Reduction of gastric pH after treatment
lasts up to 16–18 hours after administration [13] and
thereforemight interferewith the digestion and absorption
of nutrients regularly ingested by equines. Furthermore,
because lower doses, approximately one quarter of the
regular treatment dose, can prevent ulcers in equines, some
veterinarians use OMPZ more often, sometimes for longer
periods of time. However, there is no follow-up regarding
the possible side effects of PPI on the digestive process
in equines, as observed in human, because there are
numerous reports of adverse effects of PPI after short and
long periods of use [9,14,15].
The objective of the present study was to determine the
concentration of different blood biomarkers associated
with digestion in healthy horses treated with different
doses of OMPZ. Changes in some biomarkers were expected
because of the change in pH in the initial portions of the
digestive tract of the treated animals, similar to such
changes in other species.
2. Materials and Methods
2.1. Animals and Production System
Four Arabian adult nonpregnant mares were selected,
with amean age of 13 years andweight of 370 kg. Theywere
housed at the Equine Research Nucleus at Federal Rural
University of Pernambuco and were all in maintenance and
free of gastric ulcers as conﬁrmed by endoscopy. The horses
were kept at pasture with mixed grass types (cultivated and
native), with access towater andmineralized salt ad libitum,
and received commercial concentrate (crude protein, 19%;
fat, 8.0%; acid detergent ﬁber, 6.2%; neutral detergent ﬁber,
6.4%; and digestive energy, 4.1 Mcal/kg), twice daily, so that
50% of the necessary energy for animals in maintenance
could be obtained from the concentrate, according to Na-
tional Research Council [16] guidelines. All procedures were
in accordance with the guidelines for the use of animals in
experimentation of the Federal Rural University of Per-
nambuco (#62/2007-CTA/DZ).
2.2. Experimental Design
Horses were distributed randomly into a factorial
design with four animals and four treatments. The treat-
ments were controld5.0 mL of drinking water orally in
a single dose, simulating the treatment with the PPI;
OMPZBOLUSdomeprazole at 4.0 mg/kg orally in a singledose; OMPZ4mg/kgdomeprazole at 4.0 mg/kg, orally every
24 hours, for 11 days; and OMPZ1mg/kgdomeprazole at
1.0 mg/kg, orally every 24 hours, for 11 days. All experi-
mental groups were treated 16 hours before receiving
their morning concentrate (8 AM). Between treatment
rounds, horses went through a washout period of 21
days, where they remained free in the pasture, without
supplementation with concentrate and without admi-
nistration of OMPZ.
2.3. Blood Collection and Analysis of Digestive Biomarkers
and Other Metabolites
Blood samples were collected in vacuum tubes con-
taining sodium heparin in the following experimental
phases: after 12 hours of fasting and 16 hours after
administration of treatment (T1), and then 0.5 hours (T2),
1.0 hour (T3), 1.5 hours (T4), 2.0 hours (T5), 3.0 hours (T6),
4.0 hours (T7), 5.0 hours (T8), and 6.0 hours (T9) after
supplying the concentrate. The horses received an amount
of concentrate equivalent to 3.5 Mcal/digestive energy in
their morning meal. During blood collection periods,
horses had free access to water but were given no food and
were allowed to remain free in the stall.
Blood samples were immediately centrifuged, and the
plasma samples obtained were divided into two aliquots.
One was immediately used to determine glucose and
total plasma protein (TPP), and the other was frozen to
determine the concentrations of urea ([URE]), creatinine
([CREAT]), uric acid ([UrAc]), total cholesterol ([COLE-T]),
triglyceride ([TRIG]), calcium ([Ca]), phosphorus ([P]), and
magnesium ([Mg]) at a later time.
Plasma glucose concentration ([GLUC]) was measured
using a portable glucometer (Accu11 Check Advantage II,
Roche, Germany), which had been validated for use in
equines [17]. The concentration of TPP ([TPP]) was obtained
with a refractometer. Concentrations of the other bio-
markers (URE, CREAT, UrAc, COLE-T, TRIG, calcium, phos-
phorus, and magnesium) were obtained with the use of
commercial kits (Doles Reagent) and semiautomatic
biochemistry equipment (Doles D 250; Doles). The area
under the curve (AUC) for glucose was calculated according
to the method described in the literature [18,19]. The ana-
lysts had no knowledge of the experimental group towhich
the animals had been allocated.
2.4. Statistical Analysis
Results were analyzed by two-way analysis of variance
for repeated measures. Post hoc tests were performed using
Tukey test. The signiﬁcance level was set at P < .05 for all
tests. SigmaStat 3.0 (SPCC Inc, Jandel Scientiﬁc, San Rafael,
CA) for Windows 7 was used for all analyses. The results
were expressed as the means  standard error of the mean.
3. Results and Discussion
The results of this experiment demonstrated that
different doses of omeprazole (OMPZ), interfered with
the concentration of some blood biomarkers in healthy ani-
mals, even when administered 16 hours before concentrate
Table 1
Results of the analysis of variance, with two factors and for repeated
measurements, for digestive biomarkers in healthy horses control group
versus and those treated orally with omeprazole in different doses.
Biomarker Phase of
Blood
Collection
Treatment Interaction
Between Phase
and Treatment
Glucose (mmol/L) ** NS NS
Total plasma protein (g/L) NS NS NS
Total cholesterol (mg/dL) NS ** NS
Triglycerides (mg/dL) ** ** NS
Urea (mg/dL) NS ** NS
Creatinine (mg/dL) ** ** NS
Uric acid (mg/dL) NS * NS
Calcium (mg/dL) NS NS NS
Phosphorus (mg/dL) ** ** NS
Magnesium (mg/dL) NS ** NS
Abbreviation: NS, not signiﬁcant.
*P < .05; **P < .01.
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produced different effects on the concentration of the
analyzed biomarkers, and both elevated and reduced the
concentration of some biomarkers in the blood of the treated
horses, after feeding, in comparisonwith the control group.
Changes in the mean concentrations were detected
between the treatments regarding [COLE-T], [TRIG], [URE],
[CREAT], [UrAc], [P], and [Mg] (P < .05). In addition, [GLUC],
[TRIG], [CREAT], and [P] varied throughout the experi-
mental phases (P < .05). However, no signiﬁcant inter-
actions were detected between the collection phase and
the treatments for any of the analyzed biomarkers (P > .05;
Table 1). Analysis of the biomarkers that had signiﬁcant
differences between treatments showed that the horses
treated with OMPZ had changes in their lipid, protein,
and mineral metabolism compared with the control group
(P < .05; Table 2). Treatment with OMPZ4mg/kg resulted in
an increase in the biomarkers associated with lipid meta-
bolism and a decrease in the concentration of some min-
erals in the blood of treated horses; but the treatments
with OMPZ did not changed glucose concentration and AUC
for this biomarker (Table 3).
In horses treated with OMPZ, COLE-T was approxi-
mately 25% higher compared with the levels observed in
the control group, and treatment with OMPZ4mg/kg had the
highest mean concentration of this biomarker (approxi-
mately 82 mg/dL; P < .05). Triglyceride concentration wasTable 2
Results for the concentrations of digestive biomarkers in healthy control horses
Biomarker Treatment
Control OM
Glucose (mmol/L) 6.35  0.17 5.8
Total plasma protein (g/L) 6.79  0.4 6.9
Total cholesterol (mg/dL) 62.3  2.8B 81
Triglycerides (mg/dL) 27.7  1.3A 20
Urea (mg/dL) 36.8  1.0A 35
Creatinine (mg/dL) 1.16  0.02B 0.9
Uric acid (mg/dL) 0.27  0.02B 0.2
Calcium (mg/dL) 11.8  1.3 11
Phosphorus (mg/dL) 3.35  0.15A,B 3.6
Magnesium (mg/dL) 1.96  0.05A 1.6
Different superscript letters in the same line indicate P < .05, using Tukey test.higher in the control and OMPZ4mg/kg groups compared
with the other two groups (P < .05). It was also observed
that [CREAT] and [UrAc] were higher in the OMPZ4mg/kg
group, whereas in the control and OMPZBOLUS groups, [URE]
was the highest (P < .05). Control had the highest [P] and
[Mg] compared with OMPZ1mg/kg and OMPZ4mg/kg (P< .05).
[GLUC] in different experimental phases and the area
under the glucose curve did not vary between treatments
(P > .05). Only [TPP] and [Ca] did not show signiﬁcant
changes throughout the experiment either in the collection
phase or between treatments. During blood collection, the
horses had free access to water but were not given food,
and lack of changes in [PPT] could indicate that that the
animals were kept hydrated.
Suppression of gastric acidity may be associated with
changes in the digestion of fatty foods, and studies have
demonstrated that the use of PPIs such as OMPZ can result
in higher lipid absorption. This process could be associated
with the mechanism underlying suppression of gastric acid
secretion caused by OMPZ, thus elevating the lipolytic
activity of the digestive juices, resulting in higher lipid
absorption in the small intestine, similar to the process that
occurs in other species [20]. In the current experiment, a
signiﬁcant elevation in [COLE-T] was observed in the three
treated groups, although only the OMPZ4mg/kg and control
groups had a signiﬁcant elevation of [TRIG].
The detrimental effect on energetic balance of the
animals can be associated with increased acidity in the
duodenum and an accompanying decrease in activity of
pancreatic enzymes. In patients with cystic ﬁbrosis, the
elevated pH in the digestive juices can compromise diges-
tion and thus the absorption of fat by the duodenum,
compromising the energy input [2,15,21]. There are no re-
ports of a similar disease in equines; nevertheless, the
presence of elevated acidity and ulcers in the stomach
and duodenum can compromise the digestion of fats and
reduce, to a certain extent, the energy input in equine
athletes, especially those that are involved in sports where
oil is used as an important energy source [22]. However,
there are some reports in the literature inwhich gastric and
duodenal ulcers are associated with pancreatitis in foals
[23,24], but in these reports, there is no indication of
changes in the biomarkers associated with lipid digestion
and also no discussion of energetic balance or changes in
the fecal composition of these animals. Because of possibleversus those treated orally with omeprazole (OMPZ) in different doses.
PZBOLUS OMPZ1mg/kg OMPZ4mg/kg
6  0.17 6.33  0.17 6.26  0.17
0  0.4 6.92  0.4 6.89  0.4
.2  2.8A 81.7  2.8A 81.8  2.8A
.4  1.3B 19.9  1.3B 29.5  1.3A
.2  1.0A,B 32.8  1.0B,C 31.7  1.0C
5  0.02C 1.30  0.02A 1.28  0.02A
7  0.02B 0.27  0.02B 0.34  0.02A
.8  1.3 10.4  1.3 13.6  1.3
3  0.15A 2.60  0.15C 3.17  0.15B
7  0.05B 1.65  0.05B 1.76  0.05B
Table 3
Changes in the area under the curve and mean glucose concentration (mmol/L), in different phases, in healthy control horses and those treated with
omeprazole (OMPZ).
Period Treatment
Control OMPZBOLUS OMPZ1mg/kg OMPZ4mg/kg
[Glucose] in fasted horses 4.98  0.11 4.97  0.16 5.01  0.06 5.17  0.13
Maximum [glucose] 8.19  0.71 7.35  0.14 8.44  1.08 8.48  1.20
[Glucose] 6 hours after feeding 4.46  0.34 5.41  0.30 5.04  0.20 4.91  0.08
Area under the glucose curve 58.76  4.07 52.83  1.23 54.92  2.49 57.51  0.17
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better studied in horses treated with PPI that were sup-
plemented with concentrates rich in fat or oils because
such supplementation affects the energetic balance.
Finally, the disparate results between groups treated
with OMPZ in the current experiment might reﬂect, in part,
this change in the absorption of fat after treatment with
PPI. It is noteworthy that the horses treated with the
highest dose of OMPZ accumulated more COLE-T and TRIG
and could theoretically have a greater energetic input.
However, in the current experiment, only COLE-T and TRIG
were investigated. Further studies could have been con-
ducted with other biomarkers, such as free fatty acids and
glycerol, which would better clarify the effects of this
substance on the digestive process of equines.
Mineral concentration in the blood must be maintained
so that different metabolic processes can function properly.
Among minerals, [Ca] is regulated so that it is maintained
within stable parameters. There is also a relationship be-
tween calcium and other minerals, such as phosphorus
and magnesium. In the current experiment, [Ca] did not
change signiﬁcantly, unlike [P] and [Mg], after ingestion of
concentrate (P < .05). The blood concentrations of calcium,
phosphorus, and magnesium in the experimental horses
were within normal values for the species and for animals
kept in similar conditions [25,22], but the long-term effects
of these changes could have implications on the health
of speciﬁc equine groups, such as foals and athletes in
their initial phases of training, when bone metabolism is
signiﬁcant.
Studies on the effect of OMPZ on mineral metabolism in
animals are still scarce. Research in humans has demon-
strated that chronic treatment with omeprazole is directly
related to hypomagnesemia, but the mechanism underly-
ing this relationship has yet to be understood [26,9]. In the
current experiment, horses treated with OMPZ showed a
decrease in [Mg], with values approximately 10% lower
than the control group compared with the treatment
groups. It should also be noted that, evenwith the decrease
in [Mg] and [P] in the animals treated with PPI, no clinical
problems related to deﬁciency of these minerals were
observed in the experimental horses; however, the treat-
ments lasted only 11 days. The effects of the treatment with
OMPZ for longer periods should be studied in the future.
The mechanism of the observed decrease in [Mg] or
hypomagnesemia in patients treated with OMPZ and other
PPIs is not understood. There is still no clear explanation
for the decrease in [Mg] in the blood; however, case
reports regarding this disease have been associated witha decrease in calcium and zinc levels [27,28]. Consequently,
it has been suggested that patients treated with PPIs
should have their serum concentrations of some minerals
analyzed regularly [9]. Individuals with hypomagnesemia,
who are supplemented with magnesium but continue
receiving PPI, do not show an increase in blood [Mg];
however, the problem is corrected when PPI treatment is
suspended [27]. It is also known that absorption of certain
nutrients is more efﬁcient in speciﬁc areas of the intestine,
and if there are signiﬁcant changes in transit time, which
occurs following an increase in pH subsequent to PPI
treatment, a concomitant decrease in nutrient absorption
might occur. Finally, it should be noted that the ﬂuctuations
in [Mg] are complex and depend on the ability of the body
to absorb it and on the levels of renal excretion [27,9] and
that, unlike for calcium and phosphorus, its metabolism is
little investigated in horses.
Studies regarding the use of PPI have yet to clarify its
effects on protein metabolism in equines. Ingestion of
concentrated food that is rich in protein and highly
digestible, such as the concentrate used in the current
experiment, can cause changes in some biomarkers related
to protein metabolism, such as URE and CREAT [29], and
their production rate depends entirely on the protein
metabolic rate [25]. In the current experiment, mean con-
centrations for UR, CREAT, and UrAc remained within the
normal limits for the species; however, the treatment with
PPI produced an increase in [CREAT] and [UrAc] and
decrease in [URE] compared with the results found for the
control group (P < .05). This change, even considering that
the concentration was within normal limits, could be an
important indication of alterations in protein and amino
acid metabolism, and this should be taken into consider-
ation in the groups of animals that receive supplementa-
tion with a high biological value, such as foals and lactating
mares.
Chronic treatment with PPI is usually well tolerated, but
there are reports of loss of renal function. Omeprazole is
completely metabolized in the liver, and approximately
80% of the administered dose is excreted in the urine. The
rest is excreted in the bile and into the intestines [30]. This
renal excretion of OMPZ has motivated researchers to
determine the possible effects of this compound on renal
function. Recently, several authors reported that the use of
PPI is associated with loss of renal function and even acute
renal failure, with an increase in [CREAT] [31,14]. In the
present experiment, evaluation of kidney function via
urine analysis was not performed, but an increase in
[CREAT] and [UrAc] in the animals receiving OMPZ4mg/kg
S.K.M. Mélo et al. / Journal of Equine Veterinary Science 34 (2014) 1318–13231322could indicate that even after 11 days, renal function might
be impaired, as indicated by increased blood [CREAT] and
[UrAc] levels. Based on the current results, it is suggested
that renal function in equines being frequently treated
with PPI be regularly analyzed, especially if this treat-
ment is associated with the use of nonsteroidal anti-
inﬂammatory drugs. In human patients who develop
acute loss of renal function, the treatment of choice is
suspension of PPI and the use of corticosteroids, but it is
still unclear how the latter would improve renal function
[31,32]. Finally, Landray et al [32] observed that reintro-
duction of PPI produces more severe effects than the initial
presentation of loss of renal function, with more dramatic
increases in [CREAT].
Glucose is an important biomarker of carbohydrate
metabolism and must always be evaluated in the blood of
horses challenged with treatments that modify the diges-
tive process. According to Greppi et al [33], glucose in-
creases greatly a few hours after ingestion of food, but this
increase depends on the composition of the food, particu-
larly the concentration of nonstructural carbohydrates. In
the present experiment, no signiﬁcant changes in glucose
levels were observed between treatments, but there was a
natural elevation in [GLUC] after food ingestion, indicating
that the use of OMPZ did not interfere in the digestion of
soluble carbohydrates present in the concentrate. In all
treatments, the glucose peak occurred 180 minutes after
supplementation with the concentrate, a result similar to
that observed in other studies [34,35], and there were also
no signiﬁcant differences in the AUC (Table 3).4. Conclusions
In this study, oral administration of OMPZ in healthy
horses affected biomarkers associated with digestion,
related to lipid, protein, and mineral metabolism, in ani-
mals treated for a maximum of 11 days. Because of the ease
in acquiring and administering OMPZ, further research is
needed to evaluate the long-term and preventative use and
clinical signiﬁcance of this substance, both in healthy ani-
mals and those with gastric ulcers.Acknowledgments
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